INKT
MiNK Therapeutics, Inc. [INKT] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
INKT Stock Summary
Top 10 Correlated Stocks
INKT
In the News
INKT Financial details
Company Rating
Neutral
Market Cap
34.17M
Income
145.76M
Revenue
11.71B
Book val./share
-0.52
Cash/share
0.1
Dividend
-
Dividend %
-
Employees
31
Optionable
No
Shortable
Yes
Earnings
11 May 2024
P/E
0.24
Forward P/E
-
PEG
-0
P/S
-
P/B
-2.57
P/C
8.82
P/FCF
-2.01
Quick Ratio
0.62
Current Ratio
0.62
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
4.3
EPS next Y
-
EPS next Q
-
EPS this Y
-12.16%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-3.58%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
6.67%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
1.43%
Inst Trans
0.33%
ROA
1926%
ROE
-2057%
ROC
8.63%
Gross Margin
-21%
Oper. Margin
-
Profit Margin
1%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.75-3.34
52W High
-
52W Low
-
RSI
45
Rel Volume
0.37
Avg Volume
104.3K
Volume
38.47K
Perf Week
-13.57%
Perf Month
-8.36%
Perf Quarter
-3.17%
Perf Half Y
-21.98%
-
-
-
-
Beta
0.123
-
-
Volatility
0.04%, 0.16%
Prev Close
1.14%
Price
0.8816
Change
-4%
INKT Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.02 | 0 | 0 | 80.32 | 0 | |
| Net income per share | -0.78 | -0.47 | -0.69 | -0.74 | -0.65 | |
| Operating cash flow per share | -0.45 | -0.25 | -0.38 | -0.56 | -0.46 | |
| Free cash flow per share | -0.46 | -0.25 | -0.39 | -0.57 | -0.46 | |
| Cash per share | 0.01 | 0.08 | 1.16 | 0.58 | 0.1 | |
| Book value per share | -1.1 | -1.63 | 0.71 | -0.01 | -0.53 | |
| Tangible book value per share | -1.1 | -1.63 | 0.71 | -0.01 | -0.53 | |
| Share holders equity per share | -1.1 | -1.63 | 0.71 | -0.01 | -0.53 | |
| Interest debt per share | 1 | 1.4 | 0.07 | 0.01 | 0 | |
| Market cap | 397.05M | 397.05M | 149.31M | 87.89M | 36.77M | |
| Enterprise value | 423.54M | 438.18M | 110.42M | 68.25M | 33.4M | |
| P/E ratio | -15.32 | -25.32 | -6.46 | -3.55 | -1.64 | |
| Price to sales ratio | 575.74 | 0 | 0 | 0.03 | 0 | |
| POCF ratio | -26.57 | -47.62 | -11.64 | -4.66 | -2.33 | |
| PFCF ratio | -25.83 | -47.08 | -11.42 | -4.6 | -2.32 | |
| P/B Ratio | -10.93 | -7.37 | 6.28 | -219 | -2.04 | |
| PTB ratio | -10.93 | -7.37 | 6.28 | -219 | -2.04 | |
| EV to sales | 614.16 | 0 | 0 | 0.03 | 0 | |
| Enterprise value over EBITDA | -19.07 | -31.88 | -3.94 | -2.21 | -1.47 | |
| EV to operating cash flow | -28.34 | -52.55 | -8.61 | -3.62 | -2.12 | |
| EV to free cash flow | -27.55 | -51.96 | -8.44 | -3.57 | -2.11 | |
| Earnings yield | -0.07 | -0.04 | -0.15 | -0.28 | -0.61 | |
| Free cash flow yield | -0.04 | -0.02 | -0.09 | -0.22 | -0.43 | |
| Debt to equity | -0.87 | -0.81 | 0 | 0 | 0 | |
| Debt to assets | 24.1 | 9.62 | 0 | 0 | 0 | |
| Net debt to EBITDA | -1.19 | -2.99 | 1.39 | 0.64 | 0.15 | |
| Current ratio | 0.12 | 0.29 | 2.41 | 1.61 | 0.32 | |
| Interest coverage | -14.28 | -6 | -11.66 | -122.17 | 0 | |
| Income quality | 0.63 | 0.51 | 0.42 | 0.67 | 0.7 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 5.55 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 28.5 | 0 | 0 | 0.01 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.03 | 0.01 | 0.02 | 0.01 | 0 | |
| Capex to revenue | -0.62 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -11.58 | -1.73 | -3.19 | -2.05 | -0.36 | |
| Stock based compensation to revenue | 0.32 | 0 | 0 | 0 | 0 | |
| Graham number | 4.4 | 4.17 | 3.32 | 0.44 | 2.78 | |
| ROIC | 5.07 | 1.41 | -0.91 | 68.27 | 1.27 | |
| Return on tangible assets | -19.8 | -3.44 | -0.57 | -1.15 | -4.93 | |
| Graham Net | -1.12 | -1.67 | 0.67 | -0.07 | -0.56 | |
| Working capital | -6.5M | -10.13M | 23.17M | 7.72M | -7.8M | |
| Tangible asset value | -36.33M | -53.87M | 23.78M | -401.3K | -18.06M | |
| Net current asset value | -36.72M | -54.33M | 23.17M | -1.47M | -19.01M | |
| Invested capital | -0.87 | -0.81 | 0 | 0 | 0 | |
| Average receivables | 0 | 168.5K | 21.5K | 11.5K | 0 | |
| Average payables | 0 | 2.8M | 3.07M | 4.41M | 4.87M | |
| Average inventory | 0 | 559.38K | 516.41K | 880.5 | 0 | |
| Days sales outstanding | 167.78 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 20.83K | 0.04 | 0.07 | 6.98K | |
| Days of inventory on hand | 0 | 6.84K | 0 | 0 | 0 | |
| Receivables turnover | 2.18 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0.02 | 9.47K | 5.32K | 0.05 | |
| Inventory turnover | 0 | 0.05 | 16.1M | 0 | 0 | |
| ROE | 0.71 | 0.29 | -0.97 | 61.75 | 1.24 | |
| Capex per share | -0.01 | 0 | -0.01 | -0.01 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 80.01 | 344.69 | 0 | 0 | 0 | |
| Net income per share | -0.22 | 4.79 | -0.18 | -0.15 | -0.16 | |
| Operating cash flow per share | -0.13 | -0.13 | -0.12 | -0.12 | -0.09 | |
| Free cash flow per share | -0.13 | -0.13 | -0.12 | -0.12 | -0.09 | |
| Cash per share | 0.58 | 0.44 | 0.31 | 0.19 | 0.1 | |
| Book value per share | -0.01 | -0.13 | -0.28 | -0.39 | -0.52 | |
| Tangible book value per share | -0.01 | -0.13 | -0.28 | -0.39 | -0.52 | |
| Share holders equity per share | -0.01 | -0.13 | -0.28 | -0.39 | -0.52 | |
| Interest debt per share | 0 | 4.95 | 0 | 0 | 0 | |
| Market cap | 88.23M | 64.37M | 72.26M | 37.95M | 36.98M | |
| Enterprise value | 68.6M | 49.48M | 61.64M | 31.55M | 33.61M | |
| P/E ratio | -2.95 | 0.1 | -2.92 | -1.85 | -1.69 | |
| Price to sales ratio | 0.03 | 0.01 | 0 | 0 | 0 | |
| POCF ratio | -19.91 | -14.74 | -17.41 | -9.02 | -12.18 | |
| PFCF ratio | -19.36 | -14.7 | -17.25 | -8.97 | -12.18 | |
| P/B Ratio | -219.87 | -14.38 | -7.61 | -2.79 | -2.05 | |
| PTB ratio | -219.87 | -14.38 | -7.61 | -2.79 | -2.05 | |
| EV to sales | 0.03 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -8.74 | -8.52 | -9.8 | -6.1 | -6.17 | |
| EV to operating cash flow | -15.48 | -11.33 | -14.85 | -7.5 | -11.07 | |
| EV to free cash flow | -15.05 | -11.3 | -14.72 | -7.45 | -11.07 | |
| Earnings yield | -0.08 | 2.53 | -0.09 | -0.13 | -0.15 | |
| Free cash flow yield | -0.05 | -0.07 | -0.06 | -0.11 | -0.08 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 2.5 | 2.56 | 1.69 | 1.24 | 0.62 | |
| Current ratio | 1.61 | 1.38 | 0.96 | 0.62 | 0.32 | |
| Interest coverage | -49.2 | -0.03 | 0 | 0 | 0 | |
| Income quality | 0.57 | 0.77 | 0.67 | 0.82 | 0.56 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.03 | 0 | 0.01 | 0.01 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -3.37 | -0.3 | -0.71 | -0.43 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.24 | 3.77 | 1.06 | 1.15 | 1.36 | |
| ROIC | 18.95 | -37.39 | 700.26 | 0.38 | 0.3 | |
| Return on tangible assets | -0.35 | 9.8 | -0.51 | -0.69 | -1.2 | |
| Graham Net | -0.07 | -0.18 | -0.32 | -0.42 | -0.56 | |
| Working capital | 7.72M | 4.27M | -410.75K | -3.92M | -7.8M | |
| Tangible asset value | -401.3K | -4.48M | -9.5M | -13.58M | -18.06M | |
| Net current asset value | -1.47M | -5.54M | -10.55M | -14.57M | -19.01M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 5.5M | 5.91M | 5.44M | 4.58M | 4.1M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 13.82K | 0.09 | 0.07 | 0.07 | 6.57K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.01 | 975.37 | 1.3K | 1.22K | 0.01 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 18.66 | -36.31 | 0.65 | 0.38 | 0.3 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
INKT Frequently Asked Questions
What is MiNK Therapeutics, Inc. stock symbol ?
MiNK Therapeutics, Inc. is a US stock , located in New york of Ny and trading under the symbol INKT
What is MiNK Therapeutics, Inc. stock quote today ?
MiNK Therapeutics, Inc. stock price is $0.8816 today.
Is MiNK Therapeutics, Inc. stock public?
Yes, MiNK Therapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 104.3K
- Market Capitalization 34.17M
- Employee 31
- CEO Dr. Jennifer S. Buell Ph.D.
- Headquarters New York,NY,US
- IPO Date 2021-10-15
-
Website
https://minktherapeutics.com 
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
